Lead sponsor
Araclon Biotech S.L.
2 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
2
Trials led
0
Ongoing
158
Total enrollment
23
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Completed
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-ADAlzheimer's diseasePh 2Completed134
Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease PatientsAlzheimer's diseasePh 1Completed24